CoChat

Molecular Targets and Mechanisms of Radiosensitization Using DNA Damage Response Pathways

Open access
Raleigh, David R, Haas-Kogan, Daphne A · 2013 · Future Oncology
Cited by 69

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

The cellular reaction to genomic instability includes a network of signal transduction pathways collectively referred to as the DNA damage response (DDR). Activated by a variety of DNA lesions, the DDR orchestrates cell cycle arrest and DNA repair, and initiates apoptosis in instances where damage cannot be repaired. As such, disruption of the DDR increases the prevalence of DNA damage secondary to incomplete repair, and in doing so, enhances radiation-induced cytotoxicity. This article describes the molecular agents and their targets within DDR pathways that sensitize cells to radiation. Moreover, it reviews the therapeutic implications of these compounds, provides an overview of relevant clinical trials and offers a viewpoint on the evolution of the field in the years to come.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/fon.12.185

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 137

  1. 10.1080/09553009014551251 · DOI · Paper page
  2. 10.1667/0033-7587(2001)156[0577:CAFDTS]2.0.CO;2 · DOI · Paper page
  3. 10.1016/S0079-6603(08)60611-X · DOI · Paper page
  4. 10.2307/3579807 · DOI · Paper page
  5. 10.1269/jrr.07123 · DOI · Paper page
  6. 10.1080/095530098142013 · DOI
  7. 10.1667/RR0628.1 · DOI
  8. 10.1158/1078-0432.CCR-06-1269 · DOI
  9. 10.1074/jbc.273.10.5858 · DOI · Paper page
  10. 10.1016/j.cell.2007.09.041 · DOI · Paper page
  11. 10.1016/j.cell.2008.12.041 · DOI · Paper page
  12. 10.1038/13821 · DOI · Paper page
  13. 10.1074/jbc.M513265200 · DOI · Paper page
  14. 10.1038/nsmb.1639 · DOI · Paper page
  15. 10.1126/science.1192912 · DOI · Paper page
  16. 10.4161/auto.19693 · DOI · Paper page
  17. Waldman T , KinzlerKW, VogelsteinB. p21 is necessary for the p53-mediated G1 arrest in human cancer cells.Cancer Res.55(22), 5187–5190 (1995).
  18. 10.1073/pnas.172382899 · DOI · Paper page
  19. 10.4161/cc.9.3.10556 · DOI · Paper page
  20. 10.1016/j.molcel.2006.03.017 · DOI
  21. 10.1126/science.1905840 · DOI · Paper page
  22. 10.1038/nrc1881 · DOI · Paper page
  23. 10.1016/j.dnarep.2010.09.011 · DOI · Paper page
  24. 10.1016/j.febslet.2011.04.002 · DOI
  25. 10.1016/j.molonc.2011.07.002 · DOI · Paper page
  26. 10.1083/jcb.201009074 · DOI
  27. 10.1158/1078-0432.CCR-06-2793 · DOI
  28. 10.1016/j.dnarep.2009.04.012 · DOI · Paper page
  29. 10.1016/S1535-6108(03)00110-7 · DOI · Paper page
  30. 10.1074/mcp.M700006-MCP200 · DOI
  31. 10.1158/0008-5472.CAN-06-3545 · DOI · Paper page
  32. 10.1038/nature05236 · DOI · Paper page
  33. 10.1080/02841860152619115 · DOI · Paper page
  34. 10.1002/humu.20501 · DOI · Paper page
  35. 10.1093/hmg/9.4.583 · DOI
  36. 10.1016/j.dnarep.2004.03.025 · DOI · Paper page
  37. 10.1016/j.ijrobp.2009.02.057 · DOI · Paper page
  38. 10.1016/j.dnarep.2004.04.009 · DOI · Paper page
  39. 10.1097/01.md.0000229482.27398.ad · DOI · Paper page
  40. 10.1093/hmg/7.10.1555 · DOI · Paper page
  41. 10.1016/S0065-230X(08)60095-0 · DOI · Paper page
  42. 10.1038/bjc.2011.266 · DOI
  43. 10.1093/jnci/dji141 · DOI · Paper page
  44. 10.1038/ng1837 · DOI · Paper page
  45. 10.1016/S0092-8674(00)80086-0 · DOI · Paper page
  46. 10.1101/gad.10.19.2411 · DOI · Paper page
  47. 10.1083/jcb.201204098 · DOI · Paper page
  48. 10.1083/jcb.201204035 · DOI · Paper page
  49. 10.2307/3573947 · doi:10.2307/3573947
  50. 10.1148/123.2.463 · DOI · Paper page
  51. 10.1148/123.2.475 · doi:10.1148/123.2.475
  52. 10.1615/CritRevEukarGeneExpr.v19.i3.50 · DOI
  53. 10.1093/annonc/mdf280 · DOI · Paper page
  54. 10.1006/bbrc.1997.6689 · doi:10.1006/bbrc.1997.6689
  55. 10.1667/0033-7587(2001)156[0095:TOMFTN]2.0.CO;2 · DOI
  56. 10.1002/jcp.10475 · DOI
  57. 10.1002/cyto.a.20955 · DOI
  58. 10.3748/wjg.v8.i5.797 · doi:10.3748/wjg.v8.i5.797
  59. 10.2307/3576199 · DOI
  60. 10.1038/nm1096-1140 · DOI
  61. Sarkaria JN , BusbyEC, TibbettsRSet al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Research 59(17), 4375–4382 (1999).
  62. Price BD , YoumellMB. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage.Cancer Res.56(2), 246–250 (1996).
  63. Sarkaria JN , TibbettsRS, BusbyEC, KennedyAP, HillDE, AbrahamRT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin.Cancer Research58(19), 4375–4382 (1998).
  64. 10.1039/b405431h · DOI · Paper page
  65. 10.1016/S0021-9258(18)43839-2 · doi:10.1016/s0021-9258(18)43839-2
  66. 10.1074/jbc.M609603200 · DOI · Paper page
  67. 10.1016/S0021-9258(17)37680-9 · DOI · Paper page
  68. Rosenzweig KE , YoumellMB, PalayoorST, PriceBD. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2–M delay.Clin. Cancer Res.3(7), 1149–1156 (1997).
  69. Izzard RA , JacksonSP, SmithGC. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase.Cancer Res.59(11), 2581–2586 (1999).
  70. 10.1016/j.ygyno.2007.08.073 · DOI
  71. 10.2174/1568011054866937 · DOI
  72. 10.1186/1756-9966-27-76 · DOI
  73. 10.1158/1535-7163.MCT-05-0192 · DOI
  74. 10.1158/1535-7163.MCT-09-0519 · DOI · Paper page
  75. 10.4161/cc.11.6.19576 · DOI
  76. 10.4161/cbt.21093 · DOI · Paper page
  77. 10.1038/bjc.2012.265 · DOI · Paper page
  78. 10.1038/bjc.2011.243 · DOI · Paper page
  79. 10.1038/sj.onc.1204942 · DOI · Paper page
  80. 10.1038/sj.neo.7900175 · DOI
  81. 10.1038/nature10760 · DOI · Paper page
  82. 10.1074/jbc.275.8.5600 · DOI · Paper page
  83. 10.1200/JCO.2001.19.8.2319 · DOI · Paper page
  84. 10.1200/JCO.2005.03.116 · DOI
  85. 10.1158/1078-0432.CCR-04-2602 · DOI
  86. 10.1093/annonc/mdj076 · DOI
  87. 10.1182/blood-2005-08-3351 · DOI · Paper page
  88. 10.1016/j.ymthe.2005.12.009 · DOI
  89. 10.1158/1078-0432.CCR-06-1424 · DOI · Paper page
  90. 10.4161/cc.8.8.8203 · DOI
  91. 10.1158/1078-0432.CCR-09-1029 · DOI · Paper page
  92. 10.1158/1535-7163.MCT-08-0492 · DOI · Paper page
  93. 10.1158/0008-5472.CAN-09-3573 · DOI · Paper page
  94. 10.1158/1535-7163.MCT-08-0662 · DOI
  95. 10.1158/1535-7163.MCT-07-2391 · DOI · Paper page
  96. 10.4161/cc.6.1.3699 · DOI
  97. 10.1158/1535-7163.MCT-06-0371 · DOI
  98. Kohn EA , YooCJ, EastmanA. The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints.Cancer Res.63(1), 31–35 (2003).
  99. 10.1074/jbc.M309054200 · DOI · Paper page
  100. 10.1158/1535-7163.MCT-11-0406 · DOI
  101. 10.1016/j.coph.2005.04.009 · DOI · Paper page
  102. 10.2174/187152006777698132 · DOI
  103. 10.1021/jm0495935 · DOI · Paper page
  104. 10.1158/1535-7163.MCT-06-0567 · DOI
  105. 10.1124/jpet.109.154997 · DOI
  106. 10.1158/0008-5472.CAN-10-1252 · DOI · Paper page
  107. 10.1093/emboj/cdf506 · DOI · Paper page
  108. 10.1016/S1535-6108(03)00053-9 · DOI · Paper page
  109. 10.1038/ng1232 · DOI · Paper page
  110. Senderowicz AM . Novel small molecule cyclin-dependent kinases modulators in human clinical trials.Cancer Biol. Ther.2(4 Suppl. 1), S84–S95 (2003).
  111. 10.1358/dnp.2010.23.7.1490760 · DOI
  112. Wang Y , LiJ, BooherRNet al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 61(22), 8211–8217 (2001).
  113. 10.1053/jhep.2003.50112 · DOI · Paper page
  114. 10.1016/j.ccr.2010.08.011 · DOI · Paper page
  115. 10.1186/1471-2407-6-292 · DOI
  116. 10.4161/cbt.9.7.11115 · DOI · Paper page
  117. Schellens JH LeijenS ShapiroGIet al. A Phase I and pharmacological study of MK-1775 a Wee1 tyrosine kinase inhibitor in both monotherapy and in combination with gemcitabine cisplatin or carboplatin in patients with advanced solid tumors. Presented at: 2009 American Society of Clincal Oncology Annual Meeting Orlando FL USA 29 May–2 June 2009 (Abstract 3510). · doi:10.1200/jco.2009.27.15_suppl.3510
  118. 10.1186/1476-4598-8-34 · DOI
  119. 10.1093/carcin/bgi081 · DOI
  120. 10.1016/0167-8140(96)01806-3 · DOI · Paper page
  121. 10.1016/0959-8049(95)00622-2 · DOI
  122. 10.1007/s00109-007-0227-9 · DOI
  123. 10.1016/j.molcel.2011.09.026 · DOI
  124. 10.2174/092986707782360079 · DOI
  125. 10.1124/mol.108.050807 · DOI
  126. 10.1158/0008-5472.CAN-06-2181 · DOI · Paper page
  127. 10.1158/1078-0432.CCR-07-0632 · DOI
  128. 10.1158/1078-0432.CCR-08-1006 · DOI
  129. 10.1158/1078-0432.CCR-10-1927 · DOI · Paper page
  130. 10.1158/1078-0432.CCR-09-1592 · DOI
  131. 10.1074/jbc.M110.188425 · DOI
  132. 10.1158/0008-5472.CAN-08-4671 · DOI
  133. 10.1158/0008-5472.CAN-11-2866 · DOI · Paper page
  134. 10.1371/journal.pone.0034079 · DOI
  135. 10.1038/emboj.2008.127 · DOI
  136. 10.4161/cc.10.24.18661 · DOI
  137. 10.1002/ijc.27512 · DOI

Cited by

See all 69

Metadata

Authors
Raleigh, D. R., & Haas-Kogan, D. A.
Venue
Future Oncology
Published
2013-02-15
Volume
9
Issue
2
Pages
219-233
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W2009215680
Cited by
69
References
16
FWCI
2.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.